{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:23:19Z","timestamp":1793139799754,"version":"4.5.0"},"reference-count":20,"publisher":"Centers for Disease Control MMWR Office","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7132e1","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:36:26Z","timestamp":1660041386000},"page":"1011-1017","source":"Crossref","is-referenced-by-count":122,"title":["<i>Vital Signs:<\/i>\n                    Hepatitis C Treatment Among Insured Adults \u2014 United States, 2019\u20132020"],"prefix":"10.15585","volume":"71","author":[{"given":"William W.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Symum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sandul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DHSc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noele","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016.","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R2","unstructured":"CDC. Viral hepatitis surveillance 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed July 24, 2022. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/index.htm"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C.","volume":"132","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R4","unstructured":"American Association for the Study of Liver Diseases; the Infectious Disease Society of America. Recommendations for testing, managing, and treating hepatitis C. Alexandria, VA; Arlington, VA: American Association for the Study of Liver Diseases and the Infectious Disease Society of America; 2022. Accessed May 05, 2022. http:\/\/www.hcvguidelines.org"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R5","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R6","doi-asserted-by":"publisher","first-page":"e2119092","DOI":"10.1001\/jamanetworkopen.2021.19092","article-title":"Modeling hepatitis C elimination among people who inject drugs in New Hampshire.","volume":"4","author":"Blake","year":"2021","journal-title":"JAMA Netw Open"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciw075","article-title":"Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverses the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights.","volume":"62","author":"Martin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","article-title":"Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving.","volume":"15","author":"Chhatwal","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review.","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R10","doi-asserted-by":"publisher","first-page":"ciac139","DOI":"10.1093\/cid\/ciac139","article-title":"Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014\u20132020.","author":"Teshale","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R11","doi-asserted-by":"crossref","unstructured":"Strom BL, Buckley GJ, eds. A national strategy for the elimination of hepatitis B and C: phase two report. Washington, DC: National Academies Press; 2017. 10.17226\/2473128737845","DOI":"10.17226\/24731"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population.","volume":"176","author":"Chahal","year":"2016","journal-title":"JAMA Intern Med"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R14","first-page":"107","article-title":"Treating Medicaid patients with hepatitis C: clinical and economic impact.","volume":"23","author":"Younossi","year":"2017","journal-title":"Am J Manag Care"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","article-title":"Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis.","volume":"7","author":"Cunningham","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10900-017-0335-6","article-title":"Barriers to hepatitis C screening in a minority population: a comparison of hepatitis C and human immunodeficiency virus screening rates at a community STD clinic in Miami, Florida.","volume":"42","author":"Feldman","year":"2017","journal-title":"J Community Health"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/jvh.13661","article-title":"Removal of Medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.","volume":"29","author":"Nephew","year":"2022","journal-title":"J Viral Hepat"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/1468-0009.12059","article-title":"The role of stigma in access to health care for the poor.","volume":"92","author":"Allen","year":"2014","journal-title":"Milbank Q"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00038-020-01467-3","article-title":"Late presenters among minority patients with chronic hepatitis C infection in the USA.","volume":"65","author":"Pan","year":"2020","journal-title":"Int J Public Health"},{"key":"key-10.15585\/mmwr.mm7132e1-202208110808-R20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T08:26:08Z","timestamp":1660206368000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7132e1.htm?s_cid=mm7132e1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":20,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2022,8,12]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7132e1","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,12]]},"published":{"date-parts":[[2022,8,12]]}}}